Tissue factor targeted antibodies as anticoagulants
US7579000B2 · kind B2 · utility
10Cited by
18References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 30, 2004 |
| Grant date | Aug 25, 2009 |
| Priority date | — |
| Expiry date | Nov 12, 2024 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/224
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention relates to novel antibodies that bind with greater affinity to the factor VIIa/tissue factor (FVIIa/TF) complex than to tissue factor (TF) alone, do not compete for binding to TF with FVII and FX, an inhibit FX activation. The antibodies bind at the site of injury and prevent the initiation of thrombosis. The antibodies can be used to treat a variety of thrombotic conditions including but not limited to deep vein thrombosis, disseminated intravascular coagulation, and acute coronary syndrome.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.